Print pageEmail pageRSS Feeds

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
2015 | 2014 | 2013 | 2012
01/22/15ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. ... 
Printer Friendly Version
01/20/15ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe
Legally Binding Decision Follows Recommendations of Pharmacovigilance Risk Assessment Committee Review CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Jan. 20, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig® (ponatinib) following recommendations made by the Pharmacovi... 
Printer Friendly Version
01/13/15ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years
Iclusig Commercial Opportunity Expected to Expand -- Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 20... 
Printer Friendly Version
01/06/15ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
Randomized Global Trial to Evaluate Safety and Efficacy of Iclusig at Three Starting Doses CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig® (ponatinib) in patients with refractory, chronic-phase chron... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.